Next Article in Journal
Determinants of Success and Early Complications in Common Femoral Artery Endarterectomy: A Retrospective Study
Previous Article in Journal
Chyloperitoneum as the Initial Manifestation of Gastrointestinal Neoplasia
Case Report

Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review

1
Department of Surgery, Central Hospital of Beira, Beira P.O. Box 1613, Mozambique
2
Faculty of Science and Health, Catholic University of Mozambique, Beira P.O. Box CP 821, Mozambique
3
Preventive Medicine and Public Health, Universidad de La Laguna, 38201 Santa Cruz de Tenerife, Spain
4
Italian Agency for Development Cooperation-Khartoum, Khartoum 11111, Sudan
5
Department of Pediatrics, Central Hospital of Beira, Beira P.O. Box 1613, Mozambique
6
The Cambridge Centre for Sport & Exercise Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK
7
Research and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King’s Lynn PE30 4ET, UK
8
Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, 90133 Palermo, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Johannes Mayr
Received: 26 April 2021 / Revised: 6 May 2021 / Accepted: 10 May 2021 / Published: 28 May 2021
Background: Fournier’s gangrene (FG) is a rare necrotising soft tissue infection localised in the genital areas with possible dramatic outcomes. Recently, sodium glucose co-transporter-2 (SGLT2) inhibitors were identified as a risk factor. Methods: We present a case report of a 57-year-old female patient with type 2 diabetes mellitus (T2DM) in treatment with empagliflozin which led to the development of FG. Moreover, we performed a systematic review assessing the association between empagliflozin use and FG. Results: The female patient with 15-years treated diabetes presented a massive FG after 6 months from starting empagliflozin. Over the period of two months, she was successfully treated in a low-income setting. The systematic review included two studies with a total of 9915 participants. Although no participant had FG, there was an increased rate of urinary and genital infection in patients treated with empagliflozin compared to those treated with other antidiabetics or placebo. Conclusions: FG should be considered as a possible complication in patients using SGLT2. Patients should be educated to report early signs of genital infection and healthy behaviours as well as a balanced diet should be promoted to aid in the prevention of FG. View Full-Text
Keywords: empagliflozin; sodium-glucose transporter 2 inhibitors; SGLT2-inhibitors; Fournier’s gangrene; diabetes empagliflozin; sodium-glucose transporter 2 inhibitors; SGLT2-inhibitors; Fournier’s gangrene; diabetes
Show Figures

Figure 1

MDPI and ACS Style

Antunes, M.; de León, A.C.; Pizzol, D.; Seni, A.H.A.; Trott, M.; Carrie, A.M.; Ilie, P.-C.; Veronese, N.; Smith, L. Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review. Surgeries 2021, 2, 174-179. https://0-doi-org.brum.beds.ac.uk/10.3390/surgeries2020018

AMA Style

Antunes M, de León AC, Pizzol D, Seni AHA, Trott M, Carrie AM, Ilie P-C, Veronese N, Smith L. Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review. Surgeries. 2021; 2(2):174-179. https://0-doi-org.brum.beds.ac.uk/10.3390/surgeries2020018

Chicago/Turabian Style

Antunes, Mario, Antonio C. de León, Damiano Pizzol, Amir H.A. Seni, Mike Trott, Anne M. Carrie, Petre-Cristian Ilie, Nicola Veronese, and Lee Smith. 2021. "Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review" Surgeries 2, no. 2: 174-179. https://0-doi-org.brum.beds.ac.uk/10.3390/surgeries2020018

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop